We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Emergent Biosolutions (EBS) Moves 6.4% Higher: Will This Strength Last?
Read MoreHide Full Article
Emergent Biosolutions (EBS - Free Report) shares soared 6.4% in the last trading session to close at $7.51. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 26.5% loss over the past four weeks.
The rise in share prices is attributed to the FDA approval of Cyfendus, an anthrax vaccine for people aged between 18 and 65, who may have been exposed to bacillus anthracis, a harmful germ. The vaccine, previously known as AV7909, has been approved for post-exposure prophylaxis of disease following suspected or confirmed exposure to the germ, Bacillus anthracis. It is taken with recommended antibacterial medications.
This biopharmaceutical company is expected to post quarterly loss of $0.96 per share in its upcoming report, which represents a year-over-year change of -11.6%. Revenues are expected to be $209.88 million, down 13.5% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Emergent Biosolutions, the consensus EPS estimate for the quarter has been revised 3.4% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on EBS going forward to see if this recent jump can turn into more strength down the road.
Emergent Biosolutions is part of the Zacks Medical - Biomedical and Genetics industry. Qiagen (QGEN - Free Report) , another stock in the same industry, closed the last trading session 2.1% higher at $46.63. QGEN has returned 0.6% in the past month.
For Qiagen, the consensus EPS estimate for the upcoming report has changed +0.3% over the past month to $0.50. This represents a change of -2% from what the company reported a year ago. Qiagen currently has a Zacks Rank of #2 (Buy).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Emergent Biosolutions (EBS) Moves 6.4% Higher: Will This Strength Last?
Emergent Biosolutions (EBS - Free Report) shares soared 6.4% in the last trading session to close at $7.51. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 26.5% loss over the past four weeks.
The rise in share prices is attributed to the FDA approval of Cyfendus, an anthrax vaccine for people aged between 18 and 65, who may have been exposed to bacillus anthracis, a harmful germ. The vaccine, previously known as AV7909, has been approved for post-exposure prophylaxis of disease following suspected or confirmed exposure to the germ, Bacillus anthracis. It is taken with recommended antibacterial medications.
This biopharmaceutical company is expected to post quarterly loss of $0.96 per share in its upcoming report, which represents a year-over-year change of -11.6%. Revenues are expected to be $209.88 million, down 13.5% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Emergent Biosolutions, the consensus EPS estimate for the quarter has been revised 3.4% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on EBS going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Emergent Biosolutions is part of the Zacks Medical - Biomedical and Genetics industry. Qiagen (QGEN - Free Report) , another stock in the same industry, closed the last trading session 2.1% higher at $46.63. QGEN has returned 0.6% in the past month.
For Qiagen, the consensus EPS estimate for the upcoming report has changed +0.3% over the past month to $0.50. This represents a change of -2% from what the company reported a year ago. Qiagen currently has a Zacks Rank of #2 (Buy).